CRISPR Therapeutics Names A.J. Silver as New Chief Financial Officer
1 report, 1 independent
Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CRISPR Therapeutics announced that Raju Prasad will step down from his role as Chief Financial Officer to pursue external opportunities. A.J. Silver, the company's Senior Vice President of Finance, will succeed Dr. Prasad as CFO, with the transition effective immediately. Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics, welcomed A.J. Silver to the role.
From manilatimes.net
Why it matters
The transition brings new leadership to manage the financial operations and investor relations of CRISPR Therapeutics. A.J. Silver previously worked at Ernst & Young LLP, and his appointment is noted as a key leadership change within the company's finance organization.
From manilatimes.net
Who's involved
- CRISPR TherapeuticsThe company appointing the new Chief Financial Officer.
- A.J.The incoming Chief Financial Officer, who was previously employed by Ernst & Young LLP.
- Ernst & Young LLPThe firm where A.J. Silver was historically employed.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Vertex may adjust Casgevy partnership after CRISPR CFO transitionVertex may adjust financial oversight of Casgevy partnership after CRISPR CFO change.Possible
- Ark Invest may reassess CRISPR Therapeutics after CFO transitionArk Invest may adjust its view of CRISPR Therapeutics' investment riskPossible
Keep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
-
A.J.
Nothing else this week.
- Ernst & Young LLP